Product Name |
5-HT1 Receptor |
5-HT2 Receptor |
5-HT3 Receptor |
5-HT5 Receptor |
5-HT6 Receptor |
5-HT7 Receptor |
5-HT Receptor |
5-HT4 Receptor |
Purity |
Chlorpromazine hydrochloride |
|
5-HT2A Receptor, Ki: 8.9 nM
|
|
|
|
|
|
|
99.90% |
Serotonin hydrochloride |
|
|
|
|
|
|
|
|
99.97% |
Harmine |
|
5-HT2A Receptor, Ki: 397 nM
|
|
|
|
|
|
|
99.93% |
SCH-23390 hydrochloride |
|
5-HT2C Receptor, Ki: 9.3 nM
|
|
|
|
|
|
|
99.31% |
GTS-21 dihydrochloride |
|
|
5-HT3A Receptor, IC50: 3.1 μM
|
|
|
|
|
|
99.78% |
SKF-83566 |
|
5-HT2 Receptor, Ki: 11 nM
|
|
|
|
|
|
|
99.86% |
Tianeptine |
|
|
|
|
|
|
|
|
99.24% |
AVN-492 |
|
|
|
|
5-HT6 Receptor, Ki: 91 pM
|
|
|
|
99.49% |
Olanzapine |
|
5-HT2A Receptor, Ki: 4 nM
5-HT2C Receptor, Ki: 11 nM
|
5-HT3 Receptor, Ki: 57 nM
|
|
|
|
|
|
99.89% |
Risperidone |
|
5-HT2A Receptor, Ki: 4.8 nM
|
|
|
|
|
|
|
98.01% |
Thioridazine hydrochloride |
|
|
|
|
|
|
|
|
99.93% |
Puerarin |
|
|
|
|
|
|
|
|
99.20% |
Ketanserin |
|
|
|
|
|
|
|
|
98.57% |
Sertindole |
|
5-HT2A Receptor
5-HT2C Receptor
|
|
|
|
|
|
|
99.76% |
Pimavanserin |
|
5-HT2A Receptor, pIC50: 8.7
|
|
|
|
|
|
|
99.99% |
Brexpiprazole |
5-HT1A Receptor, Ki: 0.12 nM
|
5-HT2A Receptor, Ki: 0.47 nM
|
|
|
|
|
|
|
99.40% |
Aripiprazole |
5-HT1A Receptor, Ki: 4.2 nM
|
|
|
|
|
|
|
|
99.98% |
SB-269970 hydrochloride |
|
|
|
|
|
|
|
|
98.77% |
Pindolol |
|
|
|
|
|
|
|
|
99.91% |
Lurasidone |
5-HT1A Receptor, IC50: 6.75 nM
|
|
|
|
|
5-HT7 Receptor, IC50: 0.495 nM
|
|
|
99.49% |
Amitriptyline hydrochloride |
5-HT1A Receptor, IC50: 450 nM
5-HT1B Receptor, IC50: 40 nM
|
5-HT2A Receptor, IC50: 4 nM
5-HT2B Receptor, IC50: 40 nM
5-HT2C Receptor, IC50: 6 nM
|
|
|
|
|
|
|
99.56% |
Cisapride |
|
|
|
|
|
|
|
5-HT4 Receptor, EC50: 0.14 μM
|
99.72% |
Perphenazine |
|
5-HT2A Receptor, Ki: 5.6 nM
|
|
|
|
|
|
|
99.72% |
Lumateperone tosylate |
|
5-HT2A Receptor, Ki: 0.54 nM
|
|
|
|
|
|
|
99.21% |
8-OH-DPAT |
5-HT1A Receptor, pIC50: 8.19
|
|
|
|
|
5-HT7 Receptor, Ki: 466 nM
|
|
|
>98.0% |
Asenapine maleate |
|
5-HT2A Receptor, Ki: 0.06 nM
5-HT2C Receptor, Ki: 0.03 nM
|
|
|
|
5-HT7 Receptor, Ki: 0.13 nM
|
|
|
99.95% |
Methiothepin mesylate |
5-HT1A Receptor, pKd: 7.10
5-HT1B Receptor, pKd: 7.28
5-HT1C Receptor, pKd: 7.56
5-HT1D Receptor, pKd: 6.99
|
5-HT2A Receptor, pKi: 8.50
5-HT2B Receptor, pKi: 8.68
5-HT2C Receptor, pKi: 8.35
|
|
5-HT5A Receptor, pKd: 7.0
5-HT5B Receptor, pKd: 7.8
|
5-HT6 Receptor, pKd: 8.74
|
5-HT7 Receptor, pKd: 8.99
|
|
|
99.32% |
Volinanserin |
|
5-HT2 Receptor, Ki: 0.36 nM
|
|
|
|
|
|
|
99.71% |
RU 24969 |
5-HT1B Receptor, Ki: 0.38 nM
5-HT1A Receptor, Ki: 2.5 nM
|
|
|
|
|
|
|
|
99.77% |
Agomelatine |
|
5-HT2C Receptor, pKi: 6.4 (native porcine)
5-HT2C Receptor, pKi: 6.2 (human)
|
|
|
|
|
|
|
98.77% |
Alprenolol hydrochloride |
|
|
|
|
|
|
|
|
99.58% |
SB-224289 hydrochloride |
|
|
|
|
|
|
|
|
>99.0% |
Cariprazine hydrochloride |
5-HT1A Receptor, Ki: 2.6 nM
|
|
|
|
|
|
|
|
99.89% |
Ziprasidone |
Rat 5-HT1A Receptor, Ki: 3.4 nM
human 5-HT1A Receptor, Ki: 2.5 nM
|
|
|
|
|
|
|
|
98.69% |
Cyproheptadine hydrochloride |
|
|
|
|
|
|
|
|
99.98% |
Quetiapine |
5-HT1A Receptor, pKi: 5.74
5-HT1A Receptor, pEC50: 4.77
|
5-HT2A Receptor, pKi: 7.54
5-HT2C Receptor, pKi: 5.55
|
|
|
|
|
|
|
99.96% |
(Z)-Thiothixene |
|
|
|
|
|
|
|
|
99.76% |
Nefazodone hydrochloride |
|
5-HT2A Receptor, Ki: 5.8 nM
|
|
|
|
|
|
|
99.71% |
Pimavanserin tartrate |
|
5-HT2A Receptor, pIC50: 8.73
5-HT2A Receptor, pKi: 9.3
|
|
|
|
|
|
|
99.50% |
Lurasidone Hydrochloride |
5-HT1A Receptor, IC50: 6.75 nM
|
|
|
|
|
5-HT7 Receptor, IC50: 0.495 nM
|
|
|
99.87% |
Pizotifen |
|
|
|
|
|
|
|
|
99.73% |
Ondansetron |
|
|
|
|
|
|
|
|
99.41% |
Mirtazapine |
|
5-HT2 Receptor, pKi: 8.05
|
|
|
|
|
|
|
99.97% |
Paliperidone |
|
|
|
|
|
|
|
|
99.87% |
LP-211 |
5-HT1A Receptor, Ki: 188 nM
|
|
|
|
|
5-HT7 Receptor, Ki: 0.58 nM
|
|
|
99.61% |
Alprenolol |
|
|
|
|
|
|
|
|
99.87% |
Palonosetron Hydrochloride |
|
|
|
|
|
|
|
|
99.98% |
Vortioxetine hydrobromide |
|
|
5-HT3A Receptor, Ki: 3.7 nM
|
|
|
5-HT7 Receptor, Ki: 19 nM
|
|
|
99.94% |
Alosetron Hydrochloride |
|
|
|
|
|
|
|
|
99.79% |
Tegaserod maleate |
|
5-HT2B Receptor (Antagonist)
|
|
|
|
|
|
|
99.75% |
Piboserod |
|
|
|
|
|
|
|
|
99.12% |
SB 242084 |
|
5-HT2C Receptor, pKi: 9.0
|
|
|
|
|
|
|
99.47% |
Flibanserin |
5-HT1A Receptor, Ki: 1 nM
|
5-HT2A Receptor, Ki: 49 nM
|
|
|
|
|
|
|
99.10% |
Vilazodone |
|
|
|
|
|
|
|
|
99.91% |
Ketanserin tartrate |
|
|
|
|
|
|
|
|
99.97% |
Ritanserin |
|
5-HT2 Receptor, IC50: 0.9 nM
|
|
|
|
|
|
|
>99.0% |
Vortioxetine |
|
|
5-HT3A Receptor, Ki: 3.7 nM
|
|
|
Human 5-HT7 Receptor , Ki: 19 nM
|
|
|
99.52% |
Trimipramine maleate |
|
5-HT2 Receptor, pKi: 8.10
|
|
|
|
|
|
|
99.84% |
Prucalopride |
|
|
|
|
|
|
|
5-HT4A Receptor, pKi: 8.6
5-HT4B Receptor, pKi: 8.1
|
99.89% |
Mosapride citrate |
|
|
|
|
|
|
|
|
99.74% |
Idalopirdine Hydrochloride |
|
|
|
|
5-HT6 Receptor, Ki: 0.83 nM
|
|
|
|
99.83% |
Intepirdine |
|
|
|
|
5-HT6 Receptor, pKi: 9.63
|
|
|
|
98.92% |
Cinanserin hydrochloride |
|
5-HT2 Receptor, Ki: 41 nM
|
|
|
|
|
|
|
99.74% |
Vabicaserin hydrochloride |
|
5-HT2C Receptor, EC50: 8 nM
|
|
|
|
|
|
|
98.99% |
Sarpogrelate hydrochloride |
|
5-HT2A Receptor, pKi: 8.52
5-HT2B Receptor, pKi: 6.57
5-HT2C Receptor, pKi: 7.43
|
|
|
|
|
|
|
>98.0% |
2-Methyl-5-HT |
|
|
|
|
|
|
|
|
98.09% |
LY310762 |
5-HT1D Receptor, Ki: 249 nM
|
|
|
|
|
|
|
|
99.84% |
Blonanserin |
|
5-HT2A Receptor, Ki: 0.812 nM
5-HT2C Receptor, Ki: 26.4 nM
|
|
|
5-HT6 Receptor, Ki: 11.7 nM
|
|
|
|
99.77% |
Cariprazine |
5-HT1A Receptor, Ki: 2.6 nM
|
|
|
|
|
|
|
|
99.35% |
Asenapine hydrochloride |
|
5-HT2A Receptor, Ki: 0.06 nM
5-HT2C Receptor, Ki: 0.03 nM
|
|
|
|
5-HT7 Receptor, Ki: 0.13 nM
|
|
|
99.39% |
Vilazodone Hydrochloride |
|
|
|
|
|
|
|
|
99.95% |
Rotigotine |
5-HT1A Receptor, Ki: 30 nM
|
|
|
|
|
5-HT7 Receptor, Ki: 86 nM
|
|
|
99.98% |
Granisetron Hydrochloride |
|
|
5-HT3 Receptor, IC50: 17 μM
|
|
|
|
|
|
99.86% |
Eletriptan hydrobromide |
5-HT1B Receptor, Ki: 0.92 nM
5-HT1D Receptor, Ki: 3.14 nM
|
|
|
|
|
|
|
|
95.13% |
Quetiapine hemifumarate |
5-HT1A Receptor, pKi: 5.74
5-HT1A Receptor, pEC50: 4.77
|
5-HT2A Receptor, pKi: 7.54
5-HT2C Receptor, pKi: 5.55
|
|
|
|
|
|
|
98.24% |
GSK163090 |
5-HT1A Receptor, pKi: 9.4
5-HT1B Receptor, pKi: 8.5
5-HT1D Receptor, pKi: 9.7
|
5-HT2A Receptor, pKi: 6
5-HT2B Receptor, pKi: 6.3
5-HT2C Receptor, pKi: 5.8
|
|
|
Human 5-HT6 Receptor, pKi: <5.3
|
Human 5-HT7 Receptor , pKi: 6.8
|
|
|
99.95% |
NAN-190 hydrobromide |
|
|
|
|
|
|
|
|
99.02% |
SB 258719 |
|
|
|
|
|
|
|
|
99.16% |
RS-127445 hydrochloride |
|
5-HT2A Receptor, pKi: 6.3
5-HT2C Receptor, pKi: 6.4
5-HT2B Receptor, pKi: 9.5
|
|
|
|
|
|
|
99.68% |
Asenapine |
5-HT1A Receptor, pKi: 8.6
5-HT1B Receptor, pKi: 8.4
|
5-HT2A Receptor, pKi: 10.2
5-HT2C Receptor, pKi: 10.5
5-HT2B Receptor, pKi: 9.8
|
|
|
|
|
|
|
98.81% |
Tandospirone |
5-HT1A Receptor, Ki: 27 nM
|
|
|
|
|
|
|
|
99.41% |
BRL 54443 |
5-HT1E Receptor, Ki: 1.1 nM
5-HT1F Receptor, Ki: 0.7 nM
5-HT1A Receptor, Ki: 63 nM
5-HT1B Receptor, Ki: 126 nM
5-HT1D Receptor, Ki: 63 nM
|
5-HT2A Receptor, Ki: 1259 nM
5-HT2B Receptor, Ki: 100 nM
5-HT2C Receptor, Ki: 316 nM
|
|
|
5-HT6 Receptor, Ki: >10,000 nM
|
5-HT7 Receptor, Ki: >10,000 nM
|
|
|
99.39% |
Lidanserin |
|
|
|
|
|
|
|
|
>98.0% |
Setiptiline maleate |
|
5-HT2A Receptor
5-HT2C Receptor
|
|
|
|
|
|
|
98.18% |
Iloperidone |
Rat 5-HT1A Receptor, Ki: 168 nM
|
Rat 5-HT2 Receptor, Ki: 3.1 nM
Human 5-HT2A Receptor, Ki: 5.6 nM
Human 5-HT2C Receptor, Ki: 42.8 nM
|
|
|
Rat 5-HT6 Receptor, Ki: 42.7 μM
|
Rat 5-HT7 Receptor, Ki: 21.6 nM
|
|
|
99.64% |
Nuciferine |
5-HT1A Receptor, EC50: 3.2 μM
|
5-HT2C Receptor, IC50: 131 nM
5-HT2A Receptor, IC50: 478 nM
5-HT2B Receptor, IC50: 1 μM
|
|
|
5-HT6 Receptor, EC50: 700 nM
|
5-HT7 Receptor, IC50: 150 nM
|
|
|
99.66% |
SEP-363856 hydrochloride |
5-HT1A Receptor, EC50: 2.3 μM
5-HT1B Receptor, EC50: 15.6 μM
5-HT1D Receptor, EC50: 0.262 μM
|
5-HT2A Receptor, EC50: >10 μM
5-HT2C Receptor, EC50: 30 μM
|
|
|
|
5-HT7 Receptor, EC50: 6.7 μM
|
|
|
99.78% |
Nelotanserin |
|
5-HT2A Receptor, IC50: 1.7 nM
5-HT2C Receptor, IC50: 79 nM
5-HT2B Receptor, IC50: 791 nM
|
|
|
|
|
|
|
99.79% |
Pumosetrag Hydrochloride |
|
|
|
|
|
|
|
|
99.77% |
JNJ-18038683 |
|
|
|
|
|
Rat 5-HT7 Receptor, pKi: 8.19 (in HEK293 cells )
Human 5-HT7 Receptor , pKi: 8.20 (in HEK293 cells )
|
|
|
99.21% |
Temanogrel |
|
5-HT2A Receptor, Ki: 4.9 nM
|
|
|
|
|
|
|
98.94% |
Rizatriptan benzoate |
|
|
|
|
|
|
|
|
99.93% |
SB-200646A |
|
5-HT2B Receptor, pKi: 7.5
5-HT2C Receptor, pKi: 6.9
5-HT2A Receptor, pKi: 5.2
|
|
|
|
|
|
|
99.47% |
Pimethixene maleate |
5-HT1A Receptor, pKi: 7.63
|
5-HT2A Receptor, pKi: 10.22
5-HT2B Receptor, pKi: 10.44
5-HT2C Receptor, pKi: 8.42
|
|
|
|
|
|
|
>98.0% |
Sumatriptan succinate |
|
|
|
|
|
|
|
|
99.73% |
Arotinolol |
|
|
|
|
|
|
|
|
98.18% |
Adoprazine |
|
|
|
|
|
|
|
|
98.10% |
Eltoprazine hydrochloride |
5-HT1A Receptor
5-HT1B Receptor
|
|
|
|
|
|
|
|
99.85% |
LY 344864 |
5-HT1F Receptor, Ki: 6 nM
|
|
|
|
|
|
|
|
99.16% |
Talipexole dihydrochloride |
|
|
|
|
|
|
|
|
99.88% |
Ondansetron hydrochloride dihydrate |
|
|
|
|
|
|
|
|
99.87% |
LY334370 |
5-HT1F Receptor, Ki: 1.6 nM
|
|
|
|
|
|
|
|
99.80% |
Ansofaxine hydrochloride |
|
|
|
|
|
|
|
|
99.85% |
PRX-08066 |
|
5-HT2B Receptor, IC50: 3.4 nM
|
|
|
|
|
|
|
97.04% |
Tropisetron |
|
|
5-HT3 Receptor, IC50: 70.1 nM
|
|
|
|
|
|
>98.0% |
Befiradol hydrochloride |
|
|
|
|
|
|
|
|
99.22% |
Perospirone |
5-HT1A Receptor, Ki: 2.9 nM
5-HT1 Receptor, Ki: 18 nM
|
5-HT2A Receptor, Ki: 0.6 nM
|
|
|
|
|
|
|
99.51% |
Rotundine |
5-HT1A Receptor, IC50: 370 nM
|
|
|
|
|
|
|
|
99.88% |
Roluperidone |
|
5-HT2A Receptor, Ki: 7.53 nM
|
|
|
|
|
|
|
98.08% |
YL0919 |
|
|
|
|
|
|
|
|
99.77% |
Pipamperone |
|
5-HT2A Receptor, pKi: 8.2
5-HT2C Receptor, pKi: 6.9
|
|
|
|
|
|
|
99.89% |
Xanthotoxol |
|
|
|
|
|
|
|
|
99.58% |
Flopropione |
|
|
|
|
|
|
|
|
98.37% |
Bemesetron |
|
|
5-HT3 Receptor, IC50: 0.33 nM
|
|
|
|
|
|
>99.0% |
(Rac)-Rotigotine hydrochloride |
5-HT1A Receptor, Ki: 30 nM
|
5-HT2B Receptor, Ki: 27 nM
|
|
|
|
|
|
|
97.76% |
Agomelatine hydrochloride |
|
5-HT2C Receptor, pKi: 6.4 (native porcine)
5-HT2C Receptor, pKi: 6.2 (human)
|
|
|
|
|
|
|
99.49% |
Dolasetron |
|
|
|
|
|
|
|
|
>98.0% |
Alverine citrate |
5-HT1A Receptor, IC50: 101 nM
|
|
|
|
|
|
|
|
99.43% |
Cyproheptadine hydrochloride sesquihydrate |
|
|
|
|
|
|
|
|
99.20% |
Azasetron hydrochloride |
|
|
5-HT3 Receptor, IC50: 0.33 nM
|
|
|
|
|
|
99.75% |
Rotigotine Hydrochloride |
5-HT1A Receptor, Ki: 30 nM
|
|
|
|
|
5-HT7 Receptor, Ki: 86 nM
|
|
|
99.39% |
Tropisetron Hydrochloride |
|
|
5-HT3 Receptor, IC50: 70.1 nM
|
|
|
|
|
|
99.95% |
BRL-15572 dihydrochloride |
|
|
|
|
|
|
|
|
99.78% |
Ziprasidone hydrochloride monohydrate |
Rat 5-HT1A Receptor, : 3.4 nM
human 5-HT1A Receptor, : 2.5 nM
|
|
|
|
|
|
|
|
99.83% |
Methylergometrine maleate |
|
|
|
|
|
|
|
|
99.76% |
PF-04995274 |
|
|
|
|
|
|
|
|
99.42% |
Ocaperidone |
5-HT1A Receptor, pEC50: 7.6 (h5-HT1A)
5-HT1A Receptor, pKi: 8.08 (h5-HT1A)
|
5-HT2 Receptor, Ki: 0.14 nM
|
|
|
|
|
|
|
98.55% |
Phenylbiguanide |
|
|
5-HT3 Receptor, EC50: 3 μM
|
|
|
|
|
|
>98.0% |
R 59-022 |
|
|
|
|
|
|
|
|
>99.0% |
SB-399885 hydrochloride |
|
|
|
|
|
|
|
|
98.93% |
SB 271046 Hydrochloride |
5-HT1D Receptor, pKi: 6.55
5-HT1A Receptor, pKi: 6.35
5-HT1B Receptor, pKi: 6.05
5-HT1F Receptor, pKi: 5.95
5-HT1E Receptor, pKi: <4.99
|
5-HT2A Receptor, pKi: 5.62
5-HT2B Receptor, pKi: 5.41
Human 5-HT2C Receptor, pKi: 5.73
|
|
|
5-HT6 Receptor, pKi: 8.92-9.02
|
5-HT7 Receptor, pKi: 5.39
|
|
5-HT4 Receptor, pKi: 5.27
|
99.06% |
Dolasetron Mesylate hydrate |
|
|
|
|
|
|
|
|
>99.0% |
Setiptiline |
|
5-HT2A Receptor
5-HT2C Receptor
|
|
|
|
|
|
|
96.54% |
Ramosetron Hydrochloride |
|
|
|
|
|
|
|
|
99.91% |
Naftidrofuryl oxalate |
|
|
|
|
|
|
|
|
95.81% |
Pardoprunox hydrochloride |
5-HT1A Receptor, pEC50: 6.3
|
|
|
|
|
|
|
|
98.24% |
Isocorynoxeine |
|
5-HT2A Receptor, IC50: 72.4 μM
|
|
|
|
|
|
|
99.97% |
Lintopride |
|
|
|
|
|
|
|
|
96.38% |
Peptide 401 |
|
|
|
|
|
|
|
|
98.29% |
SKF-83566 hydrobromide |
|
5-HT2 Receptor, Ki: 11 nM
|
|
|
|
|
|
|
|
SB 243213 dihydrochloride |
human 5-HT1A Receptor, pKi: <5.3
human 5-HT1B Receptor, pKi: 5.5
human 5-HT1D Receptor, pKi: 6.32
human 5-HT1E Receptor, pKi: <5.4
human 5-HT1F Receptor, pKi: 5.35
|
Human 5-HT2C Receptor, pKi: 9.37
Human 5-HT2A Receptor, pKi: 7.01
human 5-HT2B Receptor, pKi: 7.2
|
|
|
Human 5-HT6 Receptor, pKi: 6.5
|
Human 5-HT7 Receptor , pKi: 5.64
|
|
|
>99.0% |
WAY-181187 |
|
|
|
|
5-HT6 Receptor, Ki: 2.2 nM
5-HT6 Receptor, EC50: 6.6 nM
|
|
|
|
98.05% |
Fabesetron |
|
|
|
|
|
|
|
|
95.72% |
Donitriptan |
5-HT1B Receptor, pKi: 9.4
5-HT1D Receptor, pKi: 9.3
|
|
|
|
|
|
|
|
|
EMD 56551 |
|
|
|
|
|
|
|
|
|
Eptapirone |
|
|
|
|
|
|
|
|
99.91% |
Syk Inhibitor II |
|
|
|
|
|
|
|
|
98.05% |
Piromelatine |
5-HT1A Receptor (Agonist)
5-HT1D Receptor (Agonist)
|
5-HT2B Receptor (Antagonist)
|
|
|
|
|
|
|
99.21% |
SB 243213 hydrochloride |
human 5-HT1A Receptor, pKi: <5.3
human 5-HT1B Receptor, pKi: 5.5
human 5-HT1D Receptor, pKi: 6.32
human 5-HT1E Receptor, pKi: <5.4
human 5-HT1F Receptor, pKi: 5.35
|
Human 5-HT2C Receptor, pKi: 9.37
Human 5-HT2A Receptor, pKi: 7.01
human 5-HT2B Receptor, pKi: 7.2
|
|
|
Human 5-HT6 Receptor, pKi: 6.5
|
Human 5-HT7 Receptor , pKi: 5.64
|
|
|
|
Urapidil |
|
|
|
|
|
|
|
|
99.89% |
Flesinoxan |
5-HT1A Receptor, EC50: 24 nM
|
|
|
|
|
|
|
|
99.07% |
OPC-14523 free base |
5-HT1A Receptor, IC50: 2.3 nM
|
|
|
|
|
|
|
|
|
Frovatriptan succinate hydrate |
5-HT1B Receptor, pEC50: 8.2
|
|
|
|
|
|
|
|
>99.0% |
OPC-14523 hydrochloride |
5-HT1A Receptor, IC50: 2.3 nM
|
|
|
|
|
|
|
|
99.90% |
Fananserin |
|
5-HT2 Receptor, Ki: 0.37 nM
|
|
|
|
|
|
|
99.71% |
Almotriptan |
5-HT1B Receptor
5-HT1D Receptor
|
|
|
|
|
|
|
|
|
p-MPPI hydrochloride |
|
|
|
|
|
|
|
|
99.19% |
SB-616234-A |
|
|
|
|
|
|
|
|
98.14% |
Almotriptan malate |
5-HT1B Receptor
5-HT1D Receptor
|
|
|
|
|
|
|
|
99.49% |
Spiramide |
5-HT1A Receptor, Ki: 50 nM
5-HT1C Receptor, Ki: 4300 nM
|
|
|
|
|
|
|
|
98.81% |
LY 344864 racemate |
|
|
|
|
|
|
|
|
98.88% |
Granisetron |
|
|
5-HT3 Receptor, IC50: 17 μM
|
|
|
|
|
|
|
Risperidone hydrochloride |
|
5-HT2 Receptor, Ki: 4.8 nM
|
|
|
|
|
|
|
|
Tianeptine sodium salt |
|
|
|
|
|
|
|
|
99.82% |
Alosetron |
|
|
|
|
|
|
|
|
|
Mosapride |
|
|
|
|
|
|
|
|
|
Eltoprazine |
5-HT1A Receptor
5-HT1B Receptor
|
|
|
|
|
|
|
|
>95.0% |
Pimethixene |
5-HT1A Receptor, pKi: 7.63
|
5-HT2A Receptor, pKi: 10.22
5-HT2B Receptor, pKi: 10.44
5-HT2C Receptor, pKi: 8.42
|
|
|
|
|
|
|
|
Palonosetron |
|
|
|
|
|
|
|
|
|
5-HT6/7 antagonist 1 |
|
|
|
|
|
|
|
|
|
Prucalopride succinate |
|
|
|
|
|
|
|
5-HT4A Receptor, pKi: 8.6
5-HT4B Receptor, pKi: 8.1
|
99.97% |
Naratriptan |
|
|
|
|
|
|
|
|
|
(±)-Fabesetron hydrochloride |
|
|
|
|
|
|
|
|
|
F-15599 |
5-HT1A Receptor, Ki: 3.4 nM
|
|
|
|
|
|
|
|
99.61% |
Urapidil hydrochloride |
|
|
|
|
|
|
|
|
>99.0% |
WAY-100635 |
5-HT1A Receptor, pIC50: 8.87
5-HT1A Receptor, pA2: 9.71
|
|
|
|
|
|
|
|
|
SB-269970 |
|
|
|
|
|
Human 5-HT7 Receptor , pKi: 8.3
|
|
|
|
RU 24969 hemisuccinate |
5-HT1A Receptor, Ki: 2.5 nM
5-HT1B Receptor, Ki: 0.38 nM
|
|
|
|
|
|
|
|
|
Spiperone hydrochloride |
5-HT1A Receptor, Ki: 49 nM
|
5-HT2A Receptor, Ki: 1 nM
|
|
|
|
|
|
|
|
Befiradol |
|
|
|
|
|
|
|
|
|
LY320135 |
|
5-HT2 Receptor, Ki: 6.4 μM
|
|
|
|
|
|
|
|
Blonanserin D5 |
|
|
|
|
|
|
|
|
|
Mirtazapine D3 |
|
|
|
|
|
|
|
|
|
Xaliproden hydrochloride |
5-HT1A Receptor, IC50: 3 nM
|
|
|
|
|
|
|
|
|
GR 125743 |
human 5-HT1B Receptor, pKi: 8.85
human 5-HT1D Receptor, pKi: 8.31
|
|
|
|
|
|
|
|
99.78% |
NPS ALX Compound 4a |
|
|
|
|
5-HT6 Receptor, IC50: 7.2 nM
5-HT6 Receptor, Ki: 0.2 nM
|
|
|
|
>99.0% |
AS19 |
5-HT1A Receptor, Ki: 89.7 nM
5-HT1B Receptor, Ki: 490 nM
5-HT1D Receptor, Ki: 6.6 nM
|
|
|
5-HT5 Receptor, Ki: 98.5 nM
|
|
Human 5-HT7 Receptor , IC50: 0.83 nM
Human 5-HT7 Receptor , Ki: 0.6 nM
|
|
|
>99.0% |
PNU-142633 |
5-HT1D Receptor, Ki: 6 nM
|
|
|
|
|
|
|
|
>98.0% |
cis-Urocanic acid |
|
|
|
|
|
|
|
|
99.92% |
SB-215505 |
|
5-HT2B Receptor, pKi: 8.3
5-HT2A Receptor, pKi: 6.77
5-HT2C Receptor, pKi: 7.66
|
|
|
|
|
|
|
|
SB 243213 |
human 5-HT1A Receptor, pKi: <5.3
human 5-HT1B Receptor, pKi: 5.5
human 5-HT1D Receptor, pKi: 6.32
human 5-HT1E Receptor, pKi: <5.4
human 5-HT1F Receptor, pKi: 5.35
|
Human 5-HT2C Receptor, pKi: 9.37
Human 5-HT2A Receptor, pKi: 7.01
human 5-HT2B Receptor, pKi: 7.2
|
|
|
Human 5-HT6 Receptor, pKi: 6.5
|
Human 5-HT7 Receptor , pKi: 5.64
|
|
|
98.62% |
3-Hydroxy agomelatine |
|
5-HT2C Receptor, IC50: 3.2 μM
5-HT2C Receptor, Ki: 1.8 μM
|
|
|
|
|
|
|
|
Isopteropodine |
|
|
|
|
|
|
|
|
|
Strictosidinic acid |
|
|
|
|
|
|
|
|
|
Masupirdine mesylate |
|
|
|
|
5-HT6 Receptor, Ki: 2.04 nM
|
|
|
|
|
Brexpiprazole S-oxide D8 |
5-HT1A Receptor, Ki: 0.12 nM
|
5-HT2A Receptor, Ki: 0.47 nM
|
|
|
|
|
|
|
|
2-Methyl-5-HT hydrochloride |
|
|
|
|
|
|
|
|
|
Cyamemazine |
|
5-HT2A Receptor, Ki: 1.5 nM
5-HT2C Receptor, Ki: 12 nM
|
5-HT3 Receptor, Ki: 75 nM
|
|
|
|
|
|
>99.0% |
Isamoltane hemifumarate |
5-HT1B Receptor, IC50: 39 nM
|
|
|
|
|
|
|
|
|
5-HT1A modulator 1 |
|
5-HT2A Receptor, IC50: 500 nM
5-HT2C Receptor, IC50: 4000 nM
|
|
|
|
|
|
|
|
Blonanserin D8 |
|
|
|
|
|
|
|
|
|
SCH-23390 maleate |
|
5-HT2C Receptor, Ki: 9.3 nM
|
|
|
|
|
|
|
|
8-Hydroxy-DPAT hydrobromide |
5-HT1A Receptor, pIC50: 8.19
|
|
|
|
|
|
|
|
|
7-Desmethyl-3-hydroxyagomelatine |
|
|
|
|
|
|
|
|
|
Geissoschizine methyl ether |
|
|
|
|
|
|
|
|
|
Flumexadol |
|
5-HT2C Receptor, Ki: 25 nM
|
|
|
|
|
|
|
98.50% |
Perospirone hydrochloride |
5-HT1A Receptor, Ki: 2.9 nM
5-HT1 Receptor, Ki: 18 nM
|
5-HT2A Receptor, Ki: 0.6 nM
|
|
|
|
|
|
|
|
SB-277011 hydrochloride |
5-HT1D Receptor
5-HT1B Receptor
|
|
|
|
|
|
|
|
98.22% |
Iferanserin |
|
|
|
|
|
|
|
|
|
Asimilobine |
|
|
|
|
|
|
|
|
|
Eplivanserin |
|
5-HT2 Receptor, IC50: 5.8 nM (in rat cortical membrane)
5-HT2 Receptor, Ki: 1.14 nM
|
|
|
|
|
|
|
|
Ro 04-6790 |
|
|
|
|
Rat 5-HT6 Receptor, pKi: 7.26
Human 5-HT6 Receptor, pKi: 7.35
|
|
|
|
|
(R)-Mirtazapine D3 |
|
|
|
|
|
|
|
|
|
Eplivanserin (mixture) |
|
|
|
|
|
|
|
|
99.95% |
Org-12962 |
|
5-HT2C Receptor, pEC50: 7.01
5-HT2A Receptor, pEC50: 6.38
5-HT2B Receptor, pEC50: 6.28
|
|
|
|
|
|
|
>98.0% |
(R)-Mirtazapine |
|
|
|
|
|
|
|
|
|
AR-A 2 |
5-HT1A Receptor, Ki: 3070 nM
5-HT1B/D Receptor, Ki: 20 nM
|
5-HT2A Receptor, Ki: 339 nM
|
|
|
|
|
|
|
|
5-Carboxamidotryptamine maleate |
5-HT1A Receptor
5-HT1B Receptor
5-HT1D Receptor
|
|
|
|
|
|
|
|
|
(Rac)-WAY-161503 |
|
5-HT2C Receptor, Ki: 4 nM
5-HT2C Receptor, EC50: 12 nM
|
|
|
|
|
|
|
>99.0% |
CART(62-76)(human,rat) |
|
|
|
|
|
|
|
|
|
Urapidil D6 |
|
|
|
|
|
|
|
|
|
TIK-301 |
|
5-HT2C Receptor
5-HT2B Receptor
|
|
|
|
|
|
|
|
Paliperidone palmitate |
|
|
|
|
|
|
|
|
98.16% |
AP521 |
5-HT1A Receptor, IC50: 94 nM (in human)
5-HT1A Receptor, IC50: 135 nM (in rat)
5-HT1B Receptor, IC50: 254 nM (in rat)
5-HT1B Receptor, IC50: 5530 nM (in human)
5-HT1D Receptor, IC50: 418 nM (in human)
|
|
|
5-HT5A Receptor, IC50: 422 nM (in human)
|
|
5-HT7 Receptor, IC50: 198 nM (in rat)
|
|
|
|
Clocapramine hydrochloride hydrate |
|
|
|
|
|
|
|
|
|
Dehydroaripiprazole |
5-HT1A Receptor, Ki: 4.2 nM
|
|
|
|
|
|
|
|
|
Opiranserin |
|
5-HT2A Receptor, IC50: 1.3 μM
|
|
|
|
|
|
|
|
BGC20-761 |
|
Human 5-HT2A Receptor, Ki: 69 nM
|
|
|
Human 5-HT6 Receptor, Ki: 20 nM
|
|
|
|
|
SB228357 |
|
5-HT2A Receptor, pKi: 6.9
5-HT2C Receptor, pKi: 9
5-HT2B Receptor, pKi: 8
|
|
|
|
|
|
|
>99.0% |
5-HT7 agonist 1 |
|
|
|
|
|
|
|
|
|
PU02 |
|
|
5-HT3A Receptor, IC50: 0.36 μM
5-HT 3 AB, IC50: 0.73 μM
|
|
|
|
|
|
99.29% |
Brilaroxazine |
5-HT1A Receptor, Ki: 1.5 nM
|
5-HT2A Receptor, Ki: 2.5 nM
5-HT2B Receptor, Ki: 0.19 nM
|
|
|
|
5-HT7 Receptor, Ki: 2.7 nM
|
|
|
|
RS-127445 |
|
5-HT2B Receptor, pKi: 9.5 nM
|
|
|
|
|
|
|
|
CART(62-76)(human,rat) TFA |
|
|
|
|
|
|
|
|
|
Facinicline hydrochloride |
|
|
5-HT3 Receptor, Ki: 1.2 nM
|
|
|
|
|
|
99.93% |
GR 113808 |
|
5-HT2A Receptor
5-HT2C Receptor
|
|
|
|
|
|
|
|
Oxatomide |
|
|
|
|
|
|
|
|
99.47% |
Org-12962 hydrochloride |
|
5-HT2C Receptor, pEC50: 7.01
5-HT2A Receptor, pEC50: 6.38
5-HT2B Receptor, pEC50: 6.28
|
|
|
|
|
|
|
|
(R)-Praziquantel D11 |
|
|
|
|
|
|
|
|
|
ML 10302 hydrochloride |
|
|
|
|
|
|
|
5-HT4 Receptor, EC50: 4 nM
|
|
Frovatriptan succinate |
5-HT1B Receptor, pEC50: 8.2
|
|
|
|
|
|
|
|
|
(S)-Mirtazapine |
|
|
|
|
|
|
|
|
|
Ipsapirone |
|
|
|
|
|
|
|
|
|
SB-200646 |
|
5-HT2B Receptor, pKi: 7.5
5-HT2C Receptor, pKi: 6.9
5-HT2A Receptor, pKi: 5.2
|
|
|
|
|
|
|
|
cis-(Z)-Flupentixol dihydrochloride |
|
5-HT2A Receptor, Ki: 7 nM
|
|
|
|
|
|
|
|
Brexpiprazole S-oxide |
5-HT1A Receptor, Ki: 0.12 nM
|
5-HT2A Receptor, Ki: 0.47 nM
|
|
|
|
|
|
|
|
Harmine hydrochloride |
|
5-HT2A Receptor, Ki: 397 nM
|
|
|
|
|
|
|
|
2-Methyl-5-HT maleate |
|
|
|
|
|
|
|
|
|
Risperidone mesylate |
|
5-HT2A Receptor, Ki: 4.8 nM
|
|
|
|
|
|
|
|
Iloperidone hydrochloride |
Rat 5-HT1A Receptor, Ki: 168 nM
|
Rat 5-HT2 Receptor, Ki: 3.1 nM
Human 5-HT2A Receptor, Ki: 5.6 nM
Human 5-HT2C Receptor, Ki: 42.8 nM
|
|
|
Rat 5-HT6 Receptor, Ki: 42.7 nM
|
Rat 5-HT7 Receptor, Ki: 21.6 nM
|
|
|
|
Agomelatine (L(+)-Tartaric acid) |
|
5-HT2C Receptor, pKi: 6.4 (native porcine)
5-HT2C Receptor, pKi: 6.2 (human)
|
|
|
|
|
|
|
99.82% |
Alosetron ((Z)-2-butenedioate) |
|
|
|
|
|
|
|
|
|
Pardoprunox |
5-HT1A Receptor, pEC50: 6.3
|
|
|
|
|
|
|
|
|
Ziprasidone hydrochloride |
Rat 5-HT1A Receptor, Ki: 3.4 nM
human 5-HT1A Receptor, Ki: 2.5 nM
|
|
|
|
|
|
|
|
|
Dolasetron Mesylate |
|
|
|
|
|
|
|
|
|
Alosetron (Hydrochloride(1:X)) |
|
|
|
|
|
|
|
|
|
Pizotifen malate |
|
|
|
|
|
|
|
|
|
Piboserod hydrochloride |
|
|
|
|
|
|
|
|
|
Lesopitron dihydrochloride |
5-HT1A Receptor, IC50: 125 nM (in rat hippocampal membranes)
|
|
|
|
|
|
|
|
|
Nexopamil racemate |
|
|
|
|
|
|
|
|
|
Deramciclane |
|
5-HT2A Receptor
5-HT2C Receptor
|
|
|
|
|
|
|
|
Clocapramine |
|
|
|
|
|
|
|
|
|
Irindalone |
|
|
|
|
|
|
|
|
|
Pancopride |
|
|
|
|
|
|
|
|
|
Sulamserod |
|
|
|
|
|
|
|
|
|
Alniditan |
5-HT1B Receptor, IC50: 1.7 nM (in HEK 293 cell)
5-HT1D Receptor, IC50: 1.3 nM (in HEK 293 cell)
|
|
|
|
|
|
|
|
|
RG-12915 |
|
|
5-HT3 Receptor, IC50: 0.16 nM
|
|
|
|
|
|
|
NEO 376 |
|
|
|
|
|
|
|
|
|
MHP 133 |
|
|
|
|
|
|
|
|
|
T 82 |
|
|
|
|
|
|
|
|
|
Ondansetron hydrochloride |
|
|
|
|
|
|
|
|
|
Zatosetron maleate |
|
|
|
|
|
|
|
|
|
(4E)-SUN9221 |
|
|
|
|
|
|
|
|
|
5-HT3 antagonist 1 |
|
|
|
|
|
|
|
|
|
5-HT3 antagonist 3 |
|
|
5-HT3 Receptor, Ki: 0.25 nM
|
|
|
|
|
|
|
5-HT3-In-1 |
|
|
|
|
|
|
|
|
|
5-HT2 antagonist 1 |
|
|
|
|
|
|
|
|
|
5-HT3 antagonist 2 |
|
|
|
|
|
|
|
|
|
5-HT2A antagonist 1 |
|
|
|
|
|
|
|
|
|
Revexepride |
|
|
|
|
|
|
|
|
|